AnalystsBruce JacksonBruce Jackson's Stock Forecasts
AnalystsBruce Jackson
Analyst Ranking
Bottom 1%
#5312 out of 5340 analysts
Average Return
-18.77%
Win Rate
28%38 out of 134
Risk vs Reward
Poor
Good
Bruce Jackson's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Insight Molecular Diagnostics IncIMDX | +252.05% | $29.20 | $102.80 | 2020-07-30 - 2021-07-30 | Buy |
Belite Bio IncBLTE | +251.13% | $14.14 | $49.65 | 2023-06-20 - 2024-06-18 | Strong Buy |
Clene IncCLNN | +186.43% | $2.58 | $7.39 | 2025-05-08 - 2026-05-07 | Strong Buy |
Belite Bio IncBLTE | +174.84% | $58.22 | $160.01 | 2025-01-21 - 2026-01-20 | Strong Buy |
Belite Bio IncBLTE | +168.83% | $17.90 | $48.12 | 2023-07-25 - 2024-07-24 | Strong Buy |
Bruce Jackson Analyst Color
Get additional color on Bruce Jackson's coverage of popular stocks
Bruce Jackson's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Unicycive Therapeutics IncUNCY | 10 | Buy | $13.00 | +145.28% | Maintains | a month ago |
Minimed Group IncMMED | 1 | Strong Buy | $20.00 | +10.22% | Initiates Coverage On | 3 months ago |
Neogenomics IncNEO | 7 | Strong Buy | $11.00 | -30.73% | Upgrades | 3 months ago |
Capsovision IncCV | 3 | Buy | $10.00 | +49.25% | Maintains | 4 months ago |
Abbott LaboratoriesABT | 1 | Strong Buy | $145.00 | +37.30% | Initiates Coverage On | 10 months ago |
Biofrontera IncBFRI | 8 | Strong Buy | $2.75 | N/A | Maintains | a year ago |
Humacyte IncHUMA | 15 | Strong Buy | $14.00 | N/A | Maintains | a year ago |
Harvard Bioscience IncHBIO | 6 | Buy | $30.00 | N/A | Maintains | a year ago |
Clene IncCLNN | 8 | Strong Buy | $33.00 | N/A | Maintains | a year ago |
Genelux CorpGNLX | 7 | Buy | $23.00 | N/A | Maintains | a year ago |
Belite Bio IncBLTE | 9 | Strong Buy | $80.00 | N/A | Reiterates | a year ago |
Exact Sciences CorpEXAS | 6 | Strong Buy | $65.00 | N/A | Reiterates | 2 years ago |
Milestone Scientific IncMLSS | 2 | Buy | $1.25 | N/A | Reiterates | 2 years ago |
Rocket One IncRKTO | 3 | Buy | $3.00 | N/A | Reiterates | 2 years ago |
Cytomed Therapeutics LtdGDTC | 4 | Buy | $5.00 | N/A | Reiterates | 2 years ago |
Biolase IncBIOL | 5 | Buy | $0.40 | N/A | Reiterates | 2 years ago |
Corvex IncMOVE | 2 | Buy | $300.00 | N/A | Reiterates | 2 years ago |
Cardio Diagnostics Holdings IncCDIO | 5 | Buy | $60.00 | N/A | Reiterates | 2 years ago |
Reviva Pharmaceuticals Holdings IncRVPH | 4 | Buy | $340.00 | N/A | Reiterates | 2 years ago |
Tenon Medical IncTNON | 3 | Buy | $24.00 | N/A | Reiterates | 2 years ago |
Usbc IncUSBC | 2 | Buy | $1.00 | N/A | Reiterates | 2 years ago |
Insight Molecular Diagnostics IncIMDX | 4 | Buy | $5.00 | N/A | Reiterates | 2 years ago |
Modular Medical IncMODD | 4 | Buy | $150.00 | N/A | Reiterates | 2 years ago |
Seelos Therapeutics IncSEELQ | 3 | Buy | $3,840.00 | N/A | Maintains | 3 years ago |
Skinhealth Systems IncSKIN | 7 | Strong Buy | $23.00 | N/A | Reiterates | 3 years ago |
Staar Surgical CoSTAA | 3 | Strong Buy | $75.00 | N/A | Maintains | 3 years ago |
Heartsciences IncHSCS | 1 | Buy | $800.00 | N/A | Initiates Coverage On | 4 years ago |
Invitae CorpNVTAQ | 5 | Hold | N/A | N/A | Downgrades | 4 years ago |
Biofrontera AgBFAGY | 1 | Strong Buy | $8.00 | N/A | Maintains | 6 years ago |
Chembio Diagnostics IncCEMI | 1 | Buy | $7.00 | N/A | Maintains | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.